Arcus Biosciences Announces Clinical Trial Collaboration …
WEB2 days ago · Casdatifan is being evaluated in ARC-20, a Phase 1/1b study in cancer patients, and STELLAR-009, a Phase 1b/2 study in combination with zanzalintinib in patients with advanced solid tumors ...
Arcus and AstraZeneca enter trial collaboration for renal cancer …
WEB1 day ago · AZN. Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess the combination of casdatifan (AB521) and volrustomig in patients with clear cell renal cell carcinoma ...
Arcus Biosciences - Arcus Biosciences Announces Clinical Trial ...
WEB2 days ago · HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus’s investigational HIF-2a inhibitor, in ...
Arcus Announces Clinical Trial Collaboration With AstraZeneca To ...
WEB2 days ago · Arcus Biosciences, Inc. (), Wednesday announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC."Renal cell carcinoma is a known CTLA-4-responsive tumor type, and our first-in-human study with volrustomig monotherapy demonstrated encouraging efficacy in first-line ...
Arcus Announces Clinical Trial Collaboration With AstraZeneca To ...
WEB2 days ago · (RTTNews) - Arcus Biosciences, Inc. (RCUS), Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the ...
Arcus Biosciences Announces Clinical Trial Collaboration …
WEB2 days ago · Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus’s investigational HIF-2a inhibitor, in combination with volrustomig ...
Arcus Biosciences - Arcus Biosciences Reports Second-Quarter …
WEBAug 8, 2024 · Casdatifan (HIF-2a inhibitor) Multiple expansion cohorts evaluating casdatifan in clear cell renal cell carcinoma (ccRCC) are underway, with several data presentations expected in the next 18 months. Each cohort is …
Arcus Biosciences Secures Up to $250 Million Term Loan Facility …
WEBAug 27, 2024 · The additional capital strengthens Arcus’s balance sheet and increases flexibility to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor.
Arcus Biosciences describes discovery, discloses structure
WEBAug 27, 2024 · Arcus Biosciences Inc. recently disclosed the chemical structure of AB-521 (casdatifan), an orally available small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α) in early clinical development for the treatment of advanced solid tumors with a high prevalence of molecular alterations associated with pseudohypoxia, such as clear cell ...
Arcus inks deal with AstraZeneca on ccRCC candidates
WEB1 day ago · The companies will evaluate casdatifan (AB521), Arcus’s investigational HIF-2a inhibitor, in combination with volrustomig, the UK pharma major’s investigational PD-1/CTLA-4 bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC). ... Unfettered access to industry-leading news, commentary and analysis in pharma and ...
- Some results have been removed